Changes in weight and metabolic parameters following long-term iloperidone use: A meta-analysis of data from 9 Phase II and III trials of iloperidone

Marla Hochfeld, Saeeduddin Ahmed, Xiangyi Meng, Adam Winseck

Novartis Pharmaceuticals Corporation, East Hanover, USA.

DOI: 10.4236/ojpsych.2012.224058                

Abstract

Objective: To determine the impact of iloperidone treatment on metabolic parameters. Methods: Data were analyzed from 3210 patients who received iloperidone and 587 patients who received placebo for up to 2 years during 9 Phase II and Phase III studies (integrated safety database). Patients were pooled by most frequent iloperidone dose into 3 groups: 4 - 8 mg/d, 10 - 16 mg/d, and 20 - 24 mg/d. Laboratory data from 8 studies were random (fasting and nonfasting) while patients from 1 study (n = 447) were all sampled at fasting. Results: Mean (standard deviation [SD]) weight gain from baseline to endpoint was 2.1 (6.8) kg for all patients on iloperidone. Fasting mean (SD) total cholesterol changes from baseline to end of study were 8.2 (31.6) for iloperidone and -2.2 (35.2) mg/dL for placebo. Fasting mean (SD) triglyceride changes during this period were iloperidone: -0.83 (82.3); placebo: 16.5 (113.1) mg/dL. Fasting mean (SD) glucose changes were iloperidone: 6.6 (24.0); placebo: -0.05 (17.0) mg/dL from baseline to end of study. Glycosylated hemoglobin levels were unchanged following iloperidone treatment. Conclusion: These data suggest a metabolic profile for iloperidone of modest weight gain accompanied by small changes in lipids and glucose that are unlikely to be of clinical concern.

Keywords

Dyslipidemia; Glucose; Iloperidone; Long-Term; Metabolic; Weight

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Goff, D.C., Sullivan, L.M., McEvoy, J.P., Meyer, J.M., Nasrallah, H.A., Daumit, G.L., Lamberti, S., D’Agostino, R.B., Stroup, T.S., Davis, S. and Lieberman, J.A. (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53. doi:10.1016/j.schres.2005.08.010
[2]	Oud, M.J.T. and Meyboom-de Jong, B. (2009) Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice, 10, 32-40. doi:10.1186/1471-2296-10-32
[3]	Brown, S., Barraclough, B. and Inskip, H. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217. doi:10.1192/bjp.177.3.212
[4]	Bushe, C.J., Taylor, M. and Haukka, J. (2010) Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology, 24, 17-25. doi:10.1177/1359786810382468
[5]	Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C. and Weiden, P.J. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. America Journal of Psychiatry, 156, 1686-1696.
[6]	Newcomer, J.W. (2007) Metabolic syndrome and mental illness. America Journal of Managed Care, 13, S170-S177.
[7]	Parsons, B., Allison, D.B., Loebel, A., Williams, K., Giller, E., Romano, S. and Siu, C. (2009) Weight effects associated with antipsychotics: A comprehensive database analysis. Schizophrenia Research, 110, 103-110. doi:10.1016/j.schres.2008.09.025
[8]	Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S. and Ernsberge, P. (2003) H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28, 519-526. doi:10.1038/sj.npp.1300027
[9]	American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65, 267-272. doi:10.4088/JCP.v65n0219
[10]	Weiden, P.J., Cutler, A.J., Polymeropoulos, M.H. and Wolfgang, C.D. (2008) Safety profile of iloperidone: A pooled analysis of 6-Week acute-phase pivotal trials. Journal of Clinical Psychopharmacology, 28, S12-S19. doi:10.1097/JCP.0b013e3181694f5a
[11]	Kane, J.M., Lauriello, J., Laska, E., Di Marino, M. and Wolfgang, C.D. (2008) Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 28, S29-S35. doi:10.1097/JCP.0b013e318169cca7
[12]	Potkin, S.G., Litman, R.E., Torres, R. and Wolfgang, C.D. (2008) Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology, 28, S4-S11. doi:10.1097/JCP.0b013e3181692787
[13]	Cutler, A.J., Kalali, A.H., Weiden, P.J., Hamilton, J. and Wolfgang, C.D. (2008) Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of Clinical Psychopharmacology, 28, S20-S28. doi:10.1097/JCP.0b013e318169d4ce
[14]	American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th Edition (Text Revision), American Psychiatric Association, Washington DC.
[15]	Novartis Pharmaceuticals Corporation (2012) Fanapt (iloperidone) tablets. http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf
[16]	Kongsamut, S., Roehr, J.E., Cai, J., Hartman, H.B., Weissensee, P., Kerman, L.L., Tang, L. and Sandrasagra, A. (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. European Journal of Pharmacology, 317, 417-423. doi:10.1016/S0014-2999(96)00840-0
[17]	Kalkman, H.O., Subramanian, N. and Hoyer, D. (2001) Extended radioligand binding profile of iloperidone: A broad spectrum dopamine serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology, 25, 904-914. doi:10.1016/S0893-133X(01)00285-8
[18]	Ichikawa, J., Li, Z., Dai, J. and Meltzer, H.Y. (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT receptor agonism. Brain Research, 956, 349-357. doi:10.1016/S0006-8993(02)03570-9
[19]	Roerig, J.L., Steffen, K.J. and Mitchell, J.E. (2011) Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs, 25, 1035-1059. doi:10.2165/11596300-000000000-00000
[20]	Huang, T.-L. and Lu, C.-Y. (2007) Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Medical Journal, 30, 26-32.
[21]	Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M. and Malhotra, A.K. (2009) Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents. The Journal of the American Medical Association, 302, 1765-1773. doi:10.1001/jama.2009.1549
[22]	Meyer, J.M. (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry, 63, 425-433. doi:10.4088/JCP.v63n0509
[23]	Kannel, W.B. and Vasan, R.S. (2009) Triglycerides as vascular risk factors: new epidemiologic insights for current opinion in cardiology. Current Opinion in Cardiology, 24, 345-350. doi:10.1097/HCO.0b013e32832c1284
[24]	Langsted, A., Freiberg, J.J. and Nordestgaard, B.G. (2008) Fasting and nonfasting lipid levels: Influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk. Circulation, 118, 2047-2056. doi:10.1161/CIRCULATIONAHA.108.804146
[25]	National Institutes of Health, National Heart, Lung, and Blood Institute (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf
[26]	Taylor, D., Young, C., Mohamed, R., Paton, C. and Walwyn, R. (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology, 19, 63-74. doi:10.1177/0269881105049039
[27]	Nielsen, J., Skadhede, S. and Correll, C.U. (2010) Antipsychotics associated with the development of Type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology, 35, 1997-2004. doi:10.1038/npp.2010.78